Reovirus a replication competent RNA disease has preclinical activity against melanoma lines and xenografts. Median time to progression and survival were 45 days (range 13-96 days) and 165 days (range 15 days-15.8 weeks) respectively. In conclusion reovirus treatment was well tolerated in metastatic melanoma individuals; viral replication was shown in biopsy samples. Based on preclinical… Continue reading Reovirus a replication competent RNA disease has preclinical activity against melanoma